Mithramycin (NSC 24559) therapy of testicular tumors

Autor: Harry F. Bisel, J. M. Schroeder, Donald B. Rochlin, N. C. Andrews, G. J. Hill, N. Sedransk, William S. Fletcher, W. L. Wilson
Rok vydání: 1972
Předmět:
Zdroj: Cancer. 30:900-908
ISSN: 1097-0142
0008-543X
DOI: 10.1002/1097-0142(197210)30:4<900::aid-cncr2820300407>3.0.co;2-r
Popis: A Phase II clinical trial of mithramycin was performed in 99 patients with evaluable metastatic testicular tumors. Patients received 25 μg/kg/day until therapy was stopped because of toxicity. In the absence of persistent toxicity or progression, subsequent courses were begun 4 weeks after discontinuance of the previous course. In the 74 patients with acceptable studies, responses occurred in 26% (5 complete responses and 14 partial responses). Complete responses were persistent for periods of up to 77+ months, and three patients with complete responses were alive and well at last report. Death occurred within 3 weeks after the onset of therapy in 10 patients, and coagulopathy was present in five of these patients. Toxicity of mithramycin was relatively unpredictable, and patients who exhibited severe toxicity received relatively little benefit from therapy. Responses were most common in young men with asymptomatic metastatic disease, and complete responses occurred only in patients with embryonal carcinoma.
Databáze: OpenAIRE
Externí odkaz: